A Phase 2/3 interventional study of Investigators choice of SoC and AAA817 in Prostate Cancer, sponsored by Novartis Pharmaceuticals. Recruiting at 93 sites in 13 countries. Open to male participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Prostatic Neoplasms by Novartis — 13 open to participants now, 25 under way, 4 of them phase 3. Prostatic Neoplasms · Novartis.
Among the 82 studies in Prostatic Neoplasms by Novartis, this one is the 10th largest by planned enrollment of the 70 interventional ones that give a count, is one of 11 that started in 2025, is one of 2 in phase 2/3, reaches primary completion later than 13 of the 24 other live ones, and was the 65th registered.
7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.
Browse Prostatic Neoplasms studies →13 of the 82 studies in Prostatic Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Switzerland
Men only
Novartis Pharmaceuticals · Sites in United States, Australia, Canada and 5 more countries
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in China
Ages 18–99 · Men only
Novartis Pharmaceuticals · Sites in United States, Canada, Czechia and 8 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Australia, France and 4 more countries
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years to 100 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 26 · Phase 3 14 · Phase 4 14
First in 1999; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 443 is above the median of 60 across 5,353 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 72 across the 70 interventional studies, 753 across the 9 observational. Of the 54 that completed or were terminated, 11 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,720 studies on the registry; 221 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
7 of the studies in Prostatic Neoplasms by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07928037Novartis PharmaceuticalsA Study of Real-world Effectiveness of 177Lu-PSMA-617 With and Without Concurrent Androgen Receptor Pathway Inhibitors in Metastatic Castration Resistant Prostate Cancer Patients | 2026-11-25 |
| NCT06991556Novartis PharmaceuticalsAn Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | 2026-12-03 |
| NCT05849298Novartis PharmaceuticalsA Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | 2026-12-23 |
| NCT04597411EndocyteStudy of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer | 2027-01-01 |
| NCT07174063Novartis PharmaceuticalsA Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer | 2027-01-29 |
Add all 7 to your calendar (.ics) → With an account.
Among the 82 studies in Prostatic Neoplasms by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after [177Lu]Lu-PSMA targeted therapy.
Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment is investigator's choice of Standard of Care, regardless of subsequent anti-neoplastic treatment
Study CAAA817A12201 consists of 2 parts: a randomized, open-label, international, multicenter, phase II study (Phase II) to collect more information to support the proposed dose of AAA817 and a randomized, open-label, international, multicenter, 2- arm phase III study (Phase III) aimed to evaluate the efficacy and safety of proposed dose of AAA817 vs. investigator's choice of standard of care (SoC) in the treatment of adult participants with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who had treatments with ARPI and taxane-based chemotherapy, and progressed on or after [177Lu]Lu-PSMA targeted therapy. The purpose of the phase II part (Phase II) of this study is to collect additional information to support proposed phase III dose of AAA817.
Inclusion Criteria: ∙
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AAA817 will be given for a number of cycles; a cycle = 8 weeks
Drug: AAA817
Participants will be given Standard of Care (SOC) treatment per Investigator's choice.
Drug: Investigators choice of SoC
AAA817 Dose A will be given for a number of cycles: a cycle = 8 weeks
Drug: AAA817
Rp3D of AAA817 will be given for a number of cycles; a cycle = 8 weeks
Drug: AAA817
The control treatment in Phase III is investigator's choice of SoC
The investigational treatment is AAA817
Also known as: [225Ac]Ac-PSMA-617)
The investigational treatment is AAA817
Also known as: [225Ac]Ac-PSMA-617)
Investigational treatment is the Dose B of AAA817
Also known as: [225Ac]Ac-PSMA-617
Biochemical response rate (Phase II)
Biochemical response rate as defined as the percentage of participants who achieved a ≥ 50% decrease from baseline that is confirmed by a second measurement
Time frame: from date of randomization up to approximately 24 months
Adverse Events (AEs) and Serious Adverse Events (SAEs), and deaths - Phase II
Safety defined as the type, incidence and severity of AEs and SAEs, and deaths
Time frame: from day of randomization to 30 days after End of Treatment or (last AAA817 dose date + 55 days, last dose date of SoC + 30 days), whichever is later
Tolerability of the proposed dose of AAA817- Phase II
Percentage of participants who experienced Dose interruptions, reductions, discontinuation, dose intensity and duration of exposure
Time frame: From on-treatment period which start from the first dose of study treatment until 30 days post-last dose date for SoC and 55 days post last-dose for AAA817
Radiographic progression-free survival (rPFS)- Phase III
Percentage of participants who are alive without radiographic progression or who are lost to follow-up at the time of analysis
Time frame: from date of randomization up to approximately 24 months
Overall survival (OS)- Phase III
Percentage of participants who are alive or who are lost to follow-up at the time of analysis
Time frame: from date of randomization up to approximately 24 months
Radiographic progression-free survival (rPFS)- Phase II
Percentage of participants who are alive without radiographic progression or who are lost to follow-up at the time of analysis
Time frame: from date of randomization up to approximately 24 months
Progression free survival (PFS)- Phase II
Percentage of Participants meeting Progression Free Survival
Time frame: from date of randomization up to approximately 24 months
Overall response rate (ORR)- Phase II
Percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR)
Time frame: from date of randomization up to approximately 24 months
Disease control rate (DCR)- Phase II
Percentage of participants with BOR of CR, PR, stable disease (SD) or non-CR/non-PD
Time frame: from date of randomization up to approximately 24 months
Overall survival (OS)- Phase II
Percentage of participants who are alive or who are lost to follow-up at the analysis data cut-off
Time frame: from date of randomization up to approximately 24 months
Progression free survival (PFS) -Phase III
Percentage of participants with PFS -defined as the time from date of randomization to first documented progression
Time frame: from date of randomization up to approximately 24 months
Overall response rate (ORR)- Phase III
ORR is defined as the percentage of participants with best overall response (BOR) of confirmed complete response (CR) or partial response (PR)
Time frame: from date of randomization up to approximately 24 months
Disease control rate (DCR) -Phase III
DCR is defined as the percentage of participants with BOR of confirmed CR, PR, stable disease (SD) or Non-CR/Non progressive disease (PD)
Time frame: from date of randomization up to approximately 24 months
Duration of response (DoR)- Phase III
Percentage of participants with confirmed DoR defined as duration of time between the date of first documented response (CR or PR) and progression or death due to any cause, whichever occurs first.
Time frame: from date of randomization up to approximately 24 months
Time to first radiographic soft tissue progression (TTSTP)- Phase III
Percentage of participants with confirmed first radiographic progression in soft tissue
Time frame: from date of randomization up to approximately 24 months
First symptomatic skeletal event (TTSSE)_Phase III
Percentage of participants with confirmed skeletal event is defined as new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, or requirement for radiation therapy to relieve bone pain, or death due to any cause, whichever occurs first
Time frame: from date of randomization up to approximately 24 months
Prostate specific antigen (PSA) response -Phase III
PSA50 is defined as the percentage of participants who achieved a confirmed ≥ 50% decrease from baseline
Time frame: from date of randomization up to approximately 24 months
Patient reported disease related symptoms and health-related quality of life (HRQoL): Phase III
Percentage of participants who had a Change from baseline on FACT-P Prostate Cancer Subscale (PCS)
Time frame: from date of randomization up to approximately 24 months
Time to worsening on the Worst Pain: Phase III
Time to worsening on the Worst Pain defined as the time from randomization to the first occurrence of worsening on the Worst Pain item (brief pain inventory - short form (BPI-SF)) of at least 30% of baseline or minimum of 2 points increase from baseline, or death due to any cause, whichever occurs first. BPI-SF is a self-reported questionnaire to evaluate pain intensity (severity) and impact of pain on the participant's daily functioning (interference).
Time frame: from date of randomization up to approximately 24 months
Started Feb 2025 (actual). Primary completion is estimated for Jun 2028, 40 months after the start.
Of 43 phase 2/3 interventional studies under Prostatic Neoplasms, half reached primary completion within 115 months of starting (the median), counting those still running; a quarter within 32. This study's planned 40 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.